Bruce Strober, MD, PhD, FAAD
About
Research
Publications
2025
Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, Papp K, Colombo M, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40045918, DOI: 10.1111/jdv.20553.Peer-Reviewed Original ResearchLong-term extension trialsLong-term extensionModerate to severe plaque psoriasisSevere plaque psoriasisPlaque psoriasisAdverse eventsTyrosine kinase 2Person yearsData cut-offYear of treatmentAdverse cardiovascular eventsTreatment of adultsPatient-reported outcomesSystemic therapyHerpes zosterSafety profileVenous thromboembolismDeucravacitinibCardiovascular eventsEfficacy resultsPatientsPsoriasisOutcome ratesExtension trialParent trialMission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis
Langley R, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, Park‐Wyllie L, Abbarin N, Tran D, Zara A, Yang Y, Strober B. Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 39985198, DOI: 10.1111/jdv.20555.Peer-Reviewed Original ResearchSpesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study
Morita A, Marrakchi S, Hu N, Thoma C, Zheng M, Tsai T, Lebwohl M, Anadkat M, Gordon K, Choon S, Burden A, Haeufel T, Thaçi D, Strober B. Spesolimab Treatment for the Prevention of Flares in People with Generalized Pustular Psoriasis (GPP): A Video Summary of the EFFISAYIL® 2 Study. Video Journal Of Biomedicine 2025 DOI: 10.1080/vjbm-2024-0012.Peer-Reviewed Original ResearchBimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period
Warren R, Lebwohl M, Thaçi D, Gooderham M, Pinter A, Paul C, Gisondi P, Szilagyi B, White K, Deherder D, Staelens F, Lambert J, Strober B. Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. British Journal Of Dermatology 2025, ljaf032. PMID: 39862230, DOI: 10.1093/bjd/ljaf032.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsOpen-label extensionComplete skin clearanceIL-17APlaque psoriasisSkin clearanceIL-17FRates of treatment-emergent adverse eventsTreatment-emergent adverse event ratesModerate to severe plaque psoriasisOpen-label extension periodSafety of bimekizumabUpper respiratory tract infectionDouble-blind periodSevere plaque psoriasisInterleukin (IL)-17ARespiratory tract infectionsYear of treatmentLong-term resultsInflammatory bowel diseaseMonoclonal IgG1 antibodyOral candidiasisClinical responseMaintenance doseTract infectionsGlobal Delphi consensus on treatment goals for generalized pustular psoriasis
Barker J, Casanova E, Choon S, Foley P, Fujita H, Gonzalez C, Gooderham M, Marrakchi S, Puig L, Romiti R, Thaçi D, Zheng M, Strober B, Magariños G, Reich A, Nakano J, Gao X, Zhang F, Sayed M, Welzel J, Gisondi P, Yaacob Y, Prignano F, Tada Y, Jo S, van der Kerkhof P, Casanova E, Rivera R, Schmitt-Egenolf M, Tsai T, Baskan E, Burden D, Mostaghimi A, Reisner D, Eyerich K, Stratigos A, Pavlovsky L, Quintero D, Imafuku S, Becker J, Affandi A, Cortés C, Carrascosa J, Wiseman M, Viguier M, Bhutani T. Global Delphi consensus on treatment goals for generalized pustular psoriasis. British Journal Of Dermatology 2025, 192: 706-716. PMID: 39844356, DOI: 10.1093/bjd/ljae491.Peer-Reviewed Original ResearchConceptsLong-term treatment goalsGeneralized pustular psoriasisPatient perspectiveTreatment goalsDelphi panelPerspectives of patientsPatient-centred approachPustular psoriasisTreatment of generalized pustular psoriasisGPP treatmentQuality of lifePrevention of life-threatening complicationsManagement of comorbiditiesPatient participationPatient representativesLife-threatening complicationsTailored treatment planSymptom burdenShort-term treatment goalsDelphi consensusNeutrophilic inflammatory diseasesSymptom controlSteering CommitteeSystematic literature reviewDisease activitySafety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Vaile J, Berger V, Vritzali E, Hoyt K, Colombo M, Scotto J, Banerjee S, Strober B, Thaçi D, Blauvelt A. Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years. JAMA Dermatology 2025, 161: 56-66. PMID: 39602111, PMCID: PMC11736510, DOI: 10.1001/jamadermatol.2024.4688.Peer-Reviewed Original ResearchLong-term extension trialsExposure-adjusted incidence ratesSevere plaque psoriasisLong-term extensionModerate to severe plaque psoriasisAdverse eventsPlaque psoriasisDouble-blind phase 3 trialStatic Physician's Global Assessment scoreDiscontinuation due to adverse eventsDay 1Physician Global Assessment scoreIncidence rateEffective long-term treatmentUpper respiratory tract infectionClinical response rateGlobal Assessment scorePhase 3 trialRespiratory tract infectionsWeeks of treatmentYear of treatmentLong-term treatmentAdverse cardiovascular eventsLong-term safetyCumulative period
2024
Considérations pour l’interprétation et la comparaison de l’efficacité à long terme des études portant sur le traitement du psoriasis modéré à sévère à l’aide d’agents biologiques
Langley R, Egeberg A, Gooderham M, Bissonnette R, Ringuet J, Kalia S, Park-Wyllie L, Abbarin N, Tran D, Zara A, Yang W, Faucher D, Strober B. Considérations pour l’interprétation et la comparaison de l’efficacité à long terme des études portant sur le traitement du psoriasis modéré à sévère à l’aide d’agents biologiques. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a247-a248. DOI: 10.1016/j.fander.2024.09.224.Peer-Reviewed Original ResearchLe deucravacitinib dans le psoriasis en plaques : résultats de tolérance et d’efficacité à 4ans dans les essais de phase 3 POETYK PSO-1, PSO-2 et dans l’étude LTE
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Imafuku S, Ohtsuki M, Spelman L, Passeron T, Papp K, Kisa R, Colombo M, Vaile J, Vritzali E, Hoyt K, Daamen C, Banerjee S, Strober B, Thaçi D, Blauvelt A. Le deucravacitinib dans le psoriasis en plaques : résultats de tolérance et d’efficacité à 4ans dans les essais de phase 3 POETYK PSO-1, PSO-2 et dans l’étude LTE. Annales De Dermatologie Et De Vénéréologie - FMC 2024, 4: a336-a338. DOI: 10.1016/j.fander.2024.09.401.Peer-Reviewed Original ResearchBrodalumab: Six-Year US Pharmacovigilance Report
Lebwohl M, Koo J, Armstrong A, Strober B, Yoon S, Rawnsley N, Goehring E, Mangin G, Jacobson A. Brodalumab: Six-Year US Pharmacovigilance Report. Dermatology And Therapy 2024, 15: 213-222. PMID: 39589679, PMCID: PMC11785849, DOI: 10.1007/s13555-024-01304-y.Peer-Reviewed Original ResearchAdverse eventsSystemic therapyUS patientsCase of Candida infectionSafety profile of brodalumabSafety of brodalumabMajor adverse cardiovascular eventsInterleukin-17 receptorAdverse cardiovascular eventsLong-term safetyFungal infection rateCandida infectionsPlaque psoriasisSafety profileAdult patientsBrodalumabCardiovascular eventsBox warningPharmacovigilance reportsFungal infectionsClinical trialsPatientsPharmacovigilance dataMedDRA QueriesClinical practiceCriteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 10: 22-27. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severity